Stents
Report clarifies deployment strategies for the crush stent technique
Published in Cardiovascular Week, January 17th, 2005
According to the report from New Zealand, "Sirolimus-eluting stents appear to reduce substantially restenosis following percutaneous coronary bifurcation intervention. The crush technique was devised to reduce restenosis further by improving stent and drug application to the side-branch ostium. We aimed to investigate the performance of drug-eluting stent (DES) platforms with the crush technique, to identify deployment pitfalls, and to clarify the best deployment strategies."
J.A. Ormiston and colleagues of Mercy Hospital in Auckland...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2005-01-17)
More Articles from Cardiovascular Week
- Antioxidants
Assay can be used to analyze or screen antioxidants against LDL oxidation - Atherosclerosis
Labedipinedilol-A may have potential in preventing progressive atherosclerosis - Collateral Arteries
Collateral recruitment has a major impact in the ischemic tolerance equation - Revascularization
Substantial differences exist concerning preoperative coronary revascularization - Statins
Participants appropriately self-selected OTC statin therapy - ACE Inhibitors
Coronary flow response to bradykinin is preserved by ACE inhibitors in aged mice - More from this issue of Cardiovascular Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
